Overview

Epzicom was a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat HIV-1 infection in combination with other antiretroviral medications. Epzicom was a combination drug composed of abacavir and lamivudine.

Abacavir and Lamivudine are both antiviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. Both drugs are believed to work by preventing HIV from replicating in cells.

How was it taken?

Prescribing information stated that Epzicom was taken once daily. Epzicom came in tablet form.

Side effects

The FDA-approved label for Epzicom listed common side effects including insomnia, depression, mood changes, fatigue, malaise, dizziness, vertigo, headache, diarrhea, and sensitivity reactions. 

Rare but serious side effects listed for Epzicom included severe hypersensitivity reactions, lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), and severe exacerbation of hepatitis B.

For more details about this treatment, visit:

Label: Epzicom — Abacavir Sulfate and Lamivudine Tablet, Film Coated — DailyMed

Overview of HIV Treatments – AIDS.gov